18F-Fluciclovine (18F-FACBC) PET imaging of recurrent brain tumors

Purpose The aim of our study was to investigate the efficacy of 18 F-Fluciclovine brain PET imaging in recurrent gliomas, and to compare the utility of these images to that of contrast enhanced magnetic resonance imaging (MRI) and to [ 11 C-methyl]-L-methionine ( 11 C-Methionine) PET imaging. We als...

Full description

Saved in:
Bibliographic Details
Published in:European journal of nuclear medicine and molecular imaging 2020-06, Vol.47 (6), p.1353-1367
Main Authors: Michaud, Laure, Beattie, B. J., Akhurst, T., Dunphy, M., Zanzonico, P., Finn, R., Mauguen, A., Schöder, H., Weber, W. A., Lassman, A. B., Blasberg, R.
Format: Article
Language:English
Subjects:
Brain
Brain cancer
Brain tumors
Cardiology
Computed tomography
Diagnostic systems
Fluorine isotopes
Glioma
Image contrast
Image enhancement
Imaging
Magnetic resonance imaging
Medical imaging
Medicine
Medicine & Public Health
Methionine
Neuroimaging
NMR
Nuclear magnetic resonance
Nuclear Medicine
Oncology
Oncology – Brain
Original
Original Article
Orthopedics
Positron emission
Positron emission tomography
Radiology
Tomography
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Purpose The aim of our study was to investigate the efficacy of 18 F-Fluciclovine brain PET imaging in recurrent gliomas, and to compare the utility of these images to that of contrast enhanced magnetic resonance imaging (MRI) and to [ 11 C-methyl]-L-methionine ( 11 C-Methionine) PET imaging. We also sought to gain insight into the factors affecting the uptake of 18 F-FACBC in both tumors and normal brain, and specifically to evaluate how the uptake in these tissues varied over an extended period of time post injection. Methods Twenty-seven patients with recurrent or progressive primary brain tumor (based on clinical and MRI/CT data) were studied using dynamic 18 F-Fluciclovine brain imaging for up to 4 h. Of these, 16 patients also had 11 C-Methionine brain scans. Visual findings, semi-quantitative analyses and pharmacokinetic modeling of a subset of the 18 F-Fluciclovine images was conducted. The information derived from these analyses were compared to data from 11 C-Methionine and to contrast-enhanced MRI. Results 18 F-Fluciclovine was positive for all 27 patients, whereas contrast MRI was indeterminate for three patients. Tumor 18 F-Fluciclovine SUVmax ranged from 1.5 to 10.5 (average: 4.5 ± 2.3), while 11 C-Methionine’s tumor SUVmax ranged from 2.2 to 10.2 (average: 5.0 ± 2.2). Image contrast was higher with 18 F-Fluciclovine compared to 11 C-Methionine ( p  
ISSN:1619-7070
1619-7089
DOI:10.1007/s00259-019-04433-1